Haematologica
Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
Ghosh N, Sehgal A, Liu FF, et al
This study was designed to investigate the comparative efficacy of lisocabtagene maraleucel in the Phase 2 PILOT study versus conventional second-line chemotherapy regimens in the real world among patients with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation. Results demonstrated consistently favorable outcomes with lisocabtagene maraleucel over real-world conventional chemotherapy regimens, reinforcing its efficacy in the second line for this patient population.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
